## Amgen Inc.

## Reconciliation of GAAP Earnings Per Share to Adjusted Earnings Per Share (Unaudited)

Results for the years ended December 31,	2003		2013	
GAAP earnings per share (diluted)	\$	1.69	\$	6.64
Adjustments to GAAP earnings per share (a):				
Acquisition-related expenses (b)		0.21		0.91
Cost savings initiatives		-		0.06
Expenses related to various legal proceedings		(0.02)		0.02
Non-cash interest expense associated with our convertible notes		-		0.01
Amgen foundation contribution		0.02		-
Other tax adjustments (c)				(0.04)
	•	4.00	•	7.00
Adjusted earnings per share (diluted)	\$	1.90	\$	7.60

- (a) The above adjustments are presented net of their related per-share tax impact of \$0.11 and \$0.49 for 2003 and 2013, respectively.
- (b) To exclude acquisition-related expenses related primarily to non-cash amortization of intangible assets, including developed product technology rights, acquired in business combinations.
- (c) The adjustments related to resolving certain non-routine transfer-pricing and acquisition-related issues with tax authorities as well as the impact related to certain prior period items excluded from adjusted earnings.

## Reconciliation of GAAP Research and Development Expenses to Adjusted Research and Development Expenses (In millions) (Unaudited)

Results for the years ended December 31,	2003		2013	
GAAP research and development expenses	\$	1,655	\$	4,083
Adjustments to research and development expenses:				
Acquisition-related expenses (d)		(34)		(142)
Stock option expense		-		(12)
Total adjustments to research and development expenses		(34)		(154)
Adjusted research and development expenses	\$	1,621	\$	3,929

(d) The 2003 adjustments related primarily to incremental costs associated with retention, integration and/or recording inventory acquired at fair value which is in excess of our standard cost. The 2013 adjustments related primarily to non-cash amortization of intangible assets acquired in prior year business combinations.